Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FMDHT
- Development stage
- Phase 1
- Lead developer
- Wake Forest University Health Sciences
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
FMDHT (7α-fluoro-17α-methyl 5α-dihydrotestosterone) is a fluorine-18 labeled radiopharmaceutical developed by Wake Forest University Health Sciences for the PET imaging of prostate cancer. It is a synthetic small molecule ligand that specifically targets the androgen receptor (AR), which is frequently overexpressed in prostate cancer cells. By binding to the AR, [F-18]FMDHT allows for the visualization and quantification of AR expression in both primary and metastatic prostate cancer lesions via PET/CT scans. The compound was designed to offer improved imaging characteristics, showing favorable kinetics with hepatobiliary excretion and minimal accumulation in the urinary bladder, which facilitates better visualization of the prostate gland and surrounding tissues compared to other tracers.
- Other names
- 7α-fluoro-17α-methyl 5α-dihydrotestosterone7a-fluoro-17a-methyl-5a-dihydrotestosterone[18F]FMDHTfluorinated methyl dihydrotestosterone
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on FMDHT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FMDHT.